OncoDaily GU

A New Article on Patient-Reported Outcomes From IMvigor011 - Enrique Grande @drenriquegrande oncodaily.com/voices/enrique…

10 Must-Read Posts in GU Oncology | Third Week of May This week’s GU oncology highlights cover: • Prostate radiotherapy automation • IMmotion150 in metastatic ccRCC • Salvage RT after prostatectomy • PSMAddition and Pluvicto • Olaparib in BRCA-mutated mCRPC • CheckMate 274 5-year update • ASCO26 oncology preview, including POTOMAC • ctDNA + utDNA in bladder-sparing MIBC • HPV evaluation in penile cancer • EV-303 / KEYNOTE-905 in cisplatin-ineligible MIBC @drenriquegrande @josedsh @amerseburger @LuigiFormisano_ @nancyghattas 📎oncodaily.com/genitourinary-… #GUOncology #OncoDaily

5-year CheckMate 274 results confirm durable DFS benefit with adjuvant nivolumab in high-risk MIUC (HR 0.74 all patients; HR 0.58 in PD-L1 ≥1%), with no new safety signals. Exploratory ctDNA analyses identify two distinct prognostic groups, supporting its potential to refine adjuvant treatment selection. #BladderCancer annalsofoncology.org/article/S0923-…

Adjuvant RT in High-Risk MIBC: Phase III Trial A multicenter phase III randomized trial in JCO evaluated adjuvant pelvic RT vs observation after radical cystectomy in high-risk urothelial MIBC. Key results: • 2-year LRFS: 87.1% vs 76.0% • HR: 0.43; P=.04 • No additional severe toxicity was reported DFS, BCSS, and OS numerically favored RT but were not statistically significant. @VedangMurthy @docpriyamvada @MahendraTMH @dramandeeparora @DrAmitJoshi_TMC @VanitaNoronha @GUpathMenon @drgaganprakash 📎oncodaily.com/wp-admin/post.… #BladderCancer #GUOncology

BART Trial Shows Benefits of Adjuvant Radiotherapy in High-Risk Bladder Cancer - Priyamvada Maitre @docpriyamvada oncodaily.com/voices/priyamv…

Real-world olaparib use in BRCA-mutated mCRPC: Dutch CAPRI-3 registry analysis: • 1,996 mCRPC patients • 23.4% underwent genomic testing • Testing varied widely: 3.8–63.2% across hospitals • BRCAm found in 53 patients • 27/35 eligible BRCAm patients received SOC olaparib • Median OS: 13.4 mo • Taxane-naïve vs post-taxane OS: 28.7 vs 10.5 mo The study highlights inconsistent genomic testing and suggests earlier olaparib use may be associated with better outcomes, though findings require cautious interpretation. @maartenvddoelen @NivenMehra @oncodaily 📎 oncodaily.com/genitourinary-… #mCRPC #OncoDaily

Bone health is becoming increasingly important in metastatic hormone-sensitive prostate cancer. A new analysis from the phase 2 BONENZA study showed that adding zoledronic acid to ADT + enzalutamide improved BMD, trabecular bone score, and bone turnover markers in men with mHSPC and bone metastases. Vertebral fractures were numerically lower with zoledronic acid, although the study was not powered to show a significant fracture reduction. Important data as treatment intensification continues in mHSPC. @g_procopio_ @oncodaily @IreneCaramella @FrancescaZacc14 📎oncodaily.com/genitourinary-… #GUOncology #OncoDaily

𝗣𝗼𝗼𝗿-𝗥𝗶𝘀𝗸 𝗧𝗲𝘀𝘁𝗶𝗰𝘂𝗹𝗮𝗿 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗕𝗲𝘆𝗼𝗻𝗱 𝗖𝗵𝗲𝗺𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 Poor-risk testicular germ cell tumors remain a major challenge, despite high cure rates in metastatic disease. Key points: • BEP or VIP remain standard first-line options • Treatment choice should reflect disease burden, pulmonary/renal risk, and mediastinal primary disease • Postchemotherapy surgery remains essential for many patients • Salvage therapy requires careful CDCT vs HDCT selection • Brain metastases need multidisciplinary care Poor-risk testicular cancer is not managed by chemotherapy alone. @Noah_Onc @aloktewar @giannatempopatr @MichaelBasinMD @nzzmda @DrDarrenFeldman @siadaneshmand 📎oncodaily.com/genitourinary-… #GUOncology

Energized by Momentum and Innovation Shaping Bladder Cancer Care after AUA 2026 - Shilpa Gupta @shilpaonc oncodaily.com/voices/shilpa-…

10 Must-Read Posts in GU Oncology | 𝗦𝗲𝗰𝗼𝗻𝗱 𝗪𝗲𝗲𝗸 𝗼𝗳 𝗠𝗮𝘆 🔑 Highlights: • 4-weekly avelumab dosing in mRCC • FDA approval of atezolizumab in ctDNA-positive MIBC • Node-positive bladder cancer and CHASIT study • WOLVERINE meta-analysis in oligometastatic PCa • VOLGA phase 3 trial in MIBC • SPIRIT trial: TRT after prostate cancer surgery • PROpel biomarker analyses in mCRPC • IMPT in high-risk prostate cancer • POTOMAC phase 3 trial in high-risk NMIBC • Fertility preservation and semen analysis in testicular cancer 💡 Precision oncology, ctDNA-guided treatment, radiotherapy innovation, survivorship, and perioperative strategies continue to reshape GU oncology. @nav_vasudev @NuvolaMD @K_Yadavir @DrChoueiri @Adam_Weiner535 @g_procopio_ @mohitmanrao 📎oncodaily.com/genitourinary-… #OncoDaily #GUOncology

Removing the Bladder is a Difficult Crossroad for Those with NMIBC - Ashish Kamat (@UroDocAsh) oncodaily.com/voices/ashish-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Two FDA approvals advance ctDNA MRD-guided adjuvant treatment in MIBC. 🟣On May 15, 2026, the FDA approved atezolizumab and atezolizumab + hyaluronidase-tqjs for adults with MIBC after cystectomy who have ctDNA MRD by an FDA-authorized test. 🟣The FDA also approved Signatera CDx as a companion diagnostic. In IMvigor011: • Median DFS: 9.9 vs 4.8 months • HR 0.64; p=0.0047 • Median OS: 32.8 vs 21.1 months • HR 0.59; p=0.0131 Takeaway: ctDNA MRD testing is becoming central to selecting patients for adjuvant treatment after cystectomy. @ArielKann @cdanicas @therealmarcodoc @AndreaNecchi @DrYukselUrun @ZoeJuneAssaf @DrElizabethSC @OncoBellmunt @oncodaily @OncoDailyIO @FDA @NateraGenetics 📎 oncodaily.com/fda-approvals/… #BladderCancer #MIBC #ctDNA #MRD #FDA #Atezolizumab #Tecentriq #Immunotherapy #Oncology

VOLGA Phase III Trial in MIBC AstraZeneca announced positive interim results from VOLGA, evaluating perioperative Imfinzi ± Imjudo with neoadjuvant enfortumab vedotin in cisplatin-ineligible or cisplatin-declining patients undergoing radical cystectomy. Key highlights: • Imfinzi + EV improved EFS and OS vs standard of care • Imfinzi + Imjudo + EV improved EFS, with a favorable OS trend not statistically significant at interim analysis • No new safety signals identified @AstraZeneca @oncodaily @OncoDailyIO @alex_drakaki @drenriquegrande @profpiotrradzi @KilianGust @h_alahmadie @ArielKann @ZakhariaYousef @MichvdHeijden 📎 oncodaily.com/oncolibrary/vo… #BladderCancer #MIBC #Oncology #Immunotherapy #ClinicalTrials #VOLGA #Imfinzi #EnfortumabVedotin

PROpel Trial: HRR Testing by Tissue and ctDNA A phase III PROpel analysis suggested that ctDNA testing can complement tumor tissue testing for detecting HRR mutations in mCRPC, especially when tissue is unavailable or insufficient. Key findings: • HRRm status obtained in 98% of randomized patients • 226 HRRm patients identified, including 85 with BRCAm • Agreement: 85.1% for HRRm, 93.9% for BRCAm @nealshore @g_procopio_ @mozguroglu @DrCraigGedye @xiaohui_li @alanbarnicle 📎oncodaily.com/oncolibrary/pr… #OncoDaily #ProstateCancer #GUOncology #mCRPC #PrecisionOncology #ctDNA #HRR #BRCA #PROpelTrial #Oncology

SPIRIT Trial Shows Potential for Testosterone Replacement After Prostate Cancer Surgery - Adam Weiner (@Adam_Weiner535) oncodaily.com/voices/adam-we… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

The Lived Experience of Bladder Cancer Patients and Insights From the Urologists Who Treat Them - Ashish Kamat (@UroDocAsh) oncodaily.com/voices/ashish-… #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedTwitter

Incredible Talk on Humoral Immunity in Kidney Cancer and Future Insights - Nick Salgia (@NickSalgia) oncodaily.com/voices/nick-sa… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

Christopher Sweeney to Lead Genitourinary Track at ESMO 2026 - European Society for Medical Oncology @myESMO @ChrisSweens1 oncodaily.com/voices/christo… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

ICI Rechallenge in mccRCC: Why Timing May Matter Global Real-World Evidence A global real-world study evaluated ICI rechallenge in metastatic clear-cell RCC. Among 6,737 patients with mccRCC, 2,773 had received ICIs, and 288 received ≥2 sequential ICI-based regimens. Patients rechallenged ≥6 months after prior ICI had better outcomes: • PFS: 8.8 vs 5.2 months • OS: 34.9 vs 19.4 months • PSM-adjusted OS association: P = 0.03 Takeaway: ICI rechallenge may remain relevant for selected patients, but timing could be key. @Anto_cigliola @BrigidaMaiorano @vale_tateo @CMercinelli @NazliDizman @neerajaiims @montypal @AndreaNecchi 📎 oncodaily.com/?p=499608&prev… #KidneyCancer #mccRCC #Immunotherapy #Oncology #ESMOOpen

FDA Must Act Now to Approve Anktiva for Papillary Bladder Cancer - Mindy Kitei (@CFSCentral) oncodaily.com/voices/mindy-k… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter